Investigational drug · Phase 2
AZD9750
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Prostate Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "AZD9750"
First trial start
2026
Jan 27, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AZD9750", any sponsor or status.
Conditions studied
As listed on its trial records.
- Prostate Cancer
Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "AZD9750" as an intervention, largest first.
- A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer DrugsActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT07336446 · 6 participants · Start Jan 27, 2026 · Primary completion Nov 5, 2026
Drug: AZD9750; AZD5305 · For: Prostate Cancer
Sites: Duarte, California; Nashville, Tennessee; Melbourne, Australia · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Discovery of AZD9750, an Orally Bioavailable Androgen Receptor Degrader for the Treatment of Prostate Cancer.
Scott JS, Evans L, Astles PC, et al. · J Med Chem 2026
Also in development for Prostate Cancer
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
- aglatimagene besadenovecCAN-2409, AdV-tkPhase 35 trials
Candel Therapeutics, Inc. · Prostate Cancer, Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
- 64Cu-SAR-bisPSMAPhase 33 trials
Clarity Pharmaceuticals Ltd · Prostate Cancer, Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasms
- Leuprorelin acetateLeuprolide Open Label, DKF-MA102Phase 33 trials
Pfizer · Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
- MevrometostatPF-06821497Phase 33 trials
Pfizer · Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.